Has the CSL share price lost its ASX 200 market darling status?

Is it time to retire the CSL share price or is it a buy at today's prices? CSL shares have remained flat overall since their March lows.

| More on:
long road with goodbye printed on it

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has been a longstanding market darling of the S&P/ASX 200 Index (ASX: XJO) and All Ordinaries (ASX: XAO). However, could it be falling out of favour against explosive tech-enabled sectors such as buy now, pay later (BNPL), the resurgence of Aussie miners or even the recent strength of retail shares? Is it time to move on or could the CSL share price be a buy at today's prices? 

Fair growth but struggling share price 

The ASX 200 has lifted more than 30% since its initial COVID-19 sell off back in March. In the same period, the CSL share price has remained flat overall. CSL's inability to push higher is perhaps a telltale sign of its fading position as a market darling. This comes as a surprise as many would consider CSL as a forever share that has delivered phenomenal long-term shareholder value. Furthermore, CSL is arguably in a market leading position to assist in the prevention and treatment of COVID-19. So why hasn't the CSL share price lifted like many other ASX 200 shares such as Fisher & Paykel Healthcare Corp Ltd (ASX: FPH), ResMed Inc (ASX: RMD), Ramsay Health Care Limited (ASX: RHC) and Sonic Healthcare Limited (ASX: SHL)?

COVID-19 business update 

From a fundamental perspective, CSL provided the market with a COVID-19 update back in mid-April. This update reaffirmed its FY20 profit guidance of ~$2.110 to $2.170 million and its strong capital position of an estimated ~$1.1 billion available in liquidity. CSL stated that its plasma collection facilities will face increasing challenges amid COVID-19 restrictions, health concerns and pre-assessment requirements. Plasma collections are a foundation for CSL revenues, however its long manufacturing cycle means that today's collections are likely to underpin sales for the next fiscal year. 

CSL's involvement in COVID-19 research, prevention and treatment remains a wildcard as the company only stated that it is pursuing COVID-19 responses consistent with its core R&D and manufacturing capabilities. The volatile environment has meant that it will experience modest delays in capital projects and clinical trials which may lag future revenues.

Foolish takeaway

All things considered, it is positive to see that CSL has reaffirmed its profit guidance. This represents FY20 growth of 10-13% which includes a one-off cost of transitioning to a new distributor model in China. Despite the CSL share price trading at a price-to-earnings (P/E) ratio of approximately 45, I believe the quality and consistency of its earnings compensates for what is arguably an expensive valuation. 

Having said that, markets and investors may be expecting more from CSL with regards to COVID-19. The likes of Fisher & Paykel, ResMed and Ramsay Healthcare have seen material improvements in their earnings since the onset of the pandemic. The fact that CSL has reaffirmed its guidance may not be enough to prop up its share price. Furthermore, the long manufacturing cycle of plasma and the potential impact on FY21 earnings could be a potential earnings season risk. 

Lina Lim has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended Ramsay Health Care Limited and Sonic Healthcare Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »